OBR Daily Commentary


FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer

(Genentech) May 29, 2020 - Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma. Tecentriq combination improved overall survival and progression-free survival compared to the previous standard of care.

Read Article arrow

Howard Hochster (Posted: May 30, 2020)


Great news for HCC patients. In the ImBRAVE150 study Child-Pugh Class A patients were randomized to Atezo-Bev vs Sorafenib. The IO combination showed improved PFS, toxicity and QoL. A real step forward for patients with HCC, not amenable to surgery or TACE.



Add Comment 1 Comment(s)